Equistone Transfers Control of Unither Pharmaceuticals to Ardian

November 28, 2016

Paris – Paul Hastings, a leading global law firm, announced that it has advised Equistone Partners Europe in connection with the sale of its majority stake in Unither Pharmaceuticals Group to the investment company Ardian France.

Unither Pharmaceuticals group is the world leader of pharmaceutical subcontracting and specializes in the manufacture of sterile single doses, various containers and generic drugs for the pharmaceutical industry. Established in France, the United States and Brazil, the Group employs nearly 1,200 people. It has a turnover of 250 million euros.

Completion is subject to the approval of the regulatory and competition authorities, as well as that of the Unither Pharmaceuticals group employees’ representatives.

The Paul Hastings team was composed of partners Olivier Deren and Sébastien Crepy and associate Valentin Savage for corporate and contractual aspects, and partner Allard de Waal and associate Thomas Pulcini for tax aspects.

Unither Pharmaceuticals group and the management team of Unither Pharmaceuticals were advised by Lamartine Conseil (Olivier Renault and Fabien Mauvais).

Ardian France was advised by the Paris office of DLA Piper (Xavier Norlain and Bertrand Levy).

Paul Hastings is a leading global law firm with a strong presence throughout Asia, Europe, Latin America, and the United States. Through a collaborative approach, entrepreneurial spirit, and commitment to client service, the professionals of Paul Hastings deliver innovative solutions to many of the world’s top financial institutions and Fortune 500 companies.